Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Published:2016-01 Issue:1 Volume:17 Page:78-89
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

du Bois Andreas,Kristensen Gunnar,Ray-Coquard Isabelle,Reuss Alexander,Pignata Sandro,Colombo Nicoletta,Denison Ursula,Vergote Ignace,del Campo Jose M,Ottevanger Petronella,Heubner Martin,Minarik Thomas,Sevin Emmanuel,de Gregorio Nikolaus,Bidziński Mariusz,Pfisterer Jacobus,Malander Susanne,Hilpert Felix,Mirza Mansoor R,Scambia Giovanni,Meier Werner,Nicoletto Maria O,Bjørge Line,Lortholary Alain,Sailer Martin Oliver,Merger Michael,Harter Philipp

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study;De Angelis;Lancet Oncol,2014

3. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade;Oberaigner;Acta Oncol,2012

4. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

5. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference;Stuart;Int J Gynecol Cancer,2011

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

3. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials;Frontiers in Pharmacology;2024-05-27

4. Effect of angiogenesis inhibitors on wound healing in patients with ovarian cancer: A meta‐analysis;International Wound Journal;2024-03

5. In Silico Approach to Molecular Profiling of the Transition from Ovarian Epithelial Cells to Low-Grade Serous Ovarian Tumors for Targeted Therapeutic Insights;Current Issues in Molecular Biology;2024-02-26